Diabetes Mellitus Flashcards

1
Q

Outline the current recommendations for DM screenings

A

Universal screening is not generally recommended.
Screening is accepted in patients who are obese, over 45 y/o, with a family history, certain minority groups (blacks, Hispanics, Pima Indians).
Screening in pregnancy is mandatory.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the classic age of onset and body habitus of DM1 vs. DM2?

A

DM1: 30 y/o, obese

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Does DM1 or DM2 develop ketoacidosis? Hyperosmolar state?

A

DM1: ketoacidosis
DM2: hyperosmolar state

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the level of endogenous insulin in DM1 vs. DM2?

A

DM1: low to none
DM2: normal to high (insulin resistance)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the twin concurrence in DM1 vs. DM2? Is there an HLA association in either one?

A

DM1: 50%, NO HLA association

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Does DM1 or DM2 respond to oral hypoglycemics?

A

DM2 responds to oral hypoglycemics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Does DM1 or DM2 have antibodies to insulin?

A

DM1 has antibodies to insulin at diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Is DM1 or DM2 at risk for diabetic complications?

A

BOTH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the islet-cell pathology in DM1 vs. DM2?

A

DM1: insulitis (loss of most B cells)
DM2: normal number, but with amyloid deposits

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the goals of treatment in terms of glucose levels?

A

Keep postprandial glucose levels less than 180 mg/dL and fasting glucose levels 70-130 mg/dL
Attempts at stricter control may result in hypoglycemia; watch for symptoms of SNS activation and mental status changes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is a good measure of long-term diabetes control?

A

Hemoglobin A1c measures “average” control of blood glucose level over the prior 2-3 months. Current recommendation is to keep it below 7.
Rough rule of thumb: Hg A1c x 20 = average blood glucose level

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

When a nondiabetic patients presents with hypoglycemia, how can you distinguish between factitious disorder (exogenous insulin) and an insulinoma (endogenous insulin)?

A

C-peptide level. C-peptide is produced whenever the body makes insulin, but is absent in prescription insulin. C-peptide will be high with an insulinoma and low with factitious disorder.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What should you remember before giving IV iodinated contrast material to a diabetic patient or a patient with renal insufficiency?

A

Prone to acute renal failure from IV contrast used for pyelography, angiography, or CT. Weigh the risk-benefit ratio. If you give contrast, hydrate patient well with IV fluids to avoid renal shutdown. Acetylcysteine and bicarbonate may decrease the risk of contrast nephropathy in high risk patients. These concerns do not apply to oral contrast agents (e.g. barium).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is diabetic ketoacidosis?

A

All type I diabetics will die without insulin, DKA happens before they die. Look for Kussmaul breathing (deep, rapid respirations), dehydration, hyperglycemia, acidosis (due to excessive ketone formation), and increased ketones in the serum (often associated with a fruity odor of the breath) and urine.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the treatment for DKA?

A

IV fluids, insulin, electrolyte replacement (esp. potassium and phosphate).
Mortality rate of DKA with current treatment efforts is less than 10%.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the most common cause of DKA?

A
  1. Insulin therapy noncompliance

2. Infection

17
Q

What is nonketotic hyperglycemic hyperosmolar state? How is it treated?

A

It is what happens to type II diabetics before they die. Hyperglycemia and increased serum osmolarity in the absence of ketones and acidosis.
Most patients are severely dehydrated; first three treatments are thus “fluids, fluids, fluids” (IV hydration with NS). Insulin and electrolyte replacement is also required. Mortality rate can approach 50% if mental status changes are present at the time of diagnosis.

18
Q

What are the classic presenting symptoms of new-onset diabetes?

A

Polyuria, polydypsia, and polyphagia (pee a lot, drink a lot, and eat a lot).
Also be suspicious if patient presents with candidal infections (e.g. thrush or vaginal yeast), weight loss (due to excessive urination), or blurry vision.
Prolonged hyperglycemia causes lenses in eyes to swell, and patient may become myopic. Older patients may even claim that they no longer need their reading glasses (i.e. presbyopia is temporarily corrected by lens swelling).

19
Q

What are the most common long-term complications of DM?

A
  • Atherosclerosis, CAD, MI. Often have “silent” heart attacks (no chest pain due to autonomic neuropathy).
  • Retinopathy. Leading cause of blindness in U.S. for persons under 50 y/o.
  • Nephropathy. #1 cause of ESRD requiring hemodialysis (30% of cases, HTN is a close second).
  • Peripheral vascular disease. Leading cause of limb amputation and may lead to claudication, stroke, and impotence.
  • Peripheral neuropathy
  • Increased risk of infection. WBC do not function as well in hyperglycemic environment. This plus inability to sense pain and clogged arteries that cannot deliver white cells to site of infection.
20
Q

What is the characteristic renal pathology in DM when viewed under micrograph?

A

Acellular Kimmelstiel-Wilson nodules
Hyalinization of arterioles which can be seen in HTN but characteristically affects BOTH efferent and afferent arterioles (vs. only afferent arterioles in HTN).

21
Q

What problems may result from diabetic peripheral neuropathy?

A
  • Gastroparesis. Because the stomach does not empty well, patients experience early satiety and vomiting. Treat with motility enhances (e.g. metoclopramide).
  • Charcot joints. Deformed secondary to lack of sensation. Patients may break a bone and not feel it.
  • Impotence
  • Cranial nerve palsies (esp. CN III, IV, and VI). Patients present with diplopia and extrocular muscle paralysis, which should resolve within 8 weeks without treatment.
  • Orthostatic hypotension. When patient is well hydrated but arteries do not “clamp down” when stands up and heart rate fails to increase.
  • Pressure ulcers in feet. Lack of sensation leads to overuse or failure to rest an injured or tired foot. Should all wear socks and comfortably fitting shoes and inspect feet regularly.
22
Q

Describe the treatment for diabetic retinopathy.

A
  • Proliferative (neovascularization or new, irregular vessel formation) - panretinal laser photocoagulation. Laser beam is used to burn tiny spots around the periphery of the retina, sparing the central retina, to prevent progression to blindness.
  • Symptomatic (macular edema) nonproliferative - focal (limited) laser photocoagulation
23
Q

What is the difference in onset of action, action peak, and total duration of action between regular insulin and NPH insulin?

A

Regular insulin: starts to work in 45 minutes, action peaks around 3-4 hours after injection, duration of action is 6-8 hours
NPH insulin: start to work in 1-1.5 hours, action peaks at 6-8 hours, duration of action is 12-20 hrs

24
Q

If the patient has high (or low) glucose at 7 AM, what insulin adjustment should you make?

A

Increase (or decrease) NPH insulin at dinner the night before

25
Q

If the patient has high (or low) noon glucose, what insulin adjustment should you make?

A

Increase (or decrease) the AM dose of regular insulin

26
Q

If the patient has high (or low) glucose at 5 PM, what insulin adjustment should you make?

A

Increase (or decrease) the AM dose of NPH insulin

27
Q

If the patient has high (or low) glucose at 9 PM, what insulin adjustment should you make?

A

Increase (or decrease) the dinner-time dose of regular insulin

28
Q

Define the Somogyi effect

A

Body’s reaction to hypoglycemia. If too much NPH insulin is given at dinner, the glucose level at 3 AM on the morning will be low. The body reacts to this by releasing stress hormones, which cause a high glucose level at 7 AM. The treatment is to decrease evening (NPH) insulin.

29
Q

Define the dawn phenomenon

A

Hyperglycemia caused by normal secretion of growth hormone early in the morning. Glucose level is high at 7 AM and normal or high at 3 AM (no hypoglycemia). The treatment is to increase evening (NPH) insulin.

30
Q

How do you manage diabetic patients who are not allowed to eat because they are scheduled for surgery?

A

Generally, 1/3-1/2 of the normal dose of insulin is given. Glucose is monitored intra- and postoperatively by the anesthesiologist. Regular IV insulin can be given to control glucose levels.

31
Q

What is the deal with beta blockers, hypoglycemia, and diabetics?

A

If you give a beta blocker to a diabetic patient, you will mask the classic symptoms of hypoglycemia (tachycardia, diaphoresis), which are caused by catecholamine release. You must weight the risk-benefit ratio of using these in diabetics. If the patient is having or has had a previous MI, the benefits outweigh the risks.

32
Q

What are the best oral agents to use in type 1 diabetes?

A

None. Patients with type 1 DM require insulin. Currently available oral agents do not work for them.

33
Q

What is the first treatment for type 2 diabetes?

A

Weight loss, because it may reduce glucose levels by reducing insulin resistance. Oral agents are tried first, typically metformin. Other agents include insulin secretagogues (glipizide, glimepiride, nateglinide, glyburide, repaglinide), thiazolidinediones (rosiglitazone, pioglitazone), alpha-glucosidase inhibitors (acarbose, miglitol), incretin mimetics (exenatide), incretin enhancers (saxagliptin, sitagliptin), and amylin analogues (pramlintide). Many type 2 diabetics eventually require insulin.